News
News Center
Chinese medicine companies ramp up R&D in stem cell therapies
来源：China News Service
2018-09-18
BEIJING, Sept. 15 (China News Service) — A traditional Chinese medicine pharmaceutical company recently signed an investment agreement with U.S.-based Cell Technology Inc. in Beijing. The partnership will introduce cutting-edge stem-cell production technology and a state-of-the-art preparation platform from the world’s leading stem-cell enterprise, with plans to build a dedicated stem-cell production facility within three to five years at the Beijing Daxing Biomedical Industry Base.
Recently, the Jiuzhitang Yonghe Qihang Fund—launched by traditional Chinese medicine company Jiuzhitang—officially signed an investment agreement with Stemedica Cell Technologies Inc., a U.S.-based company based in San Diego's Biotech Valley, which boasts over a decade of experience in stem cell research, development, manufacturing, and marketing. Currently, Jiuzhitang is constructing a allogeneic stem cell production facility in Beijing’s Daxing District, designed to meet both U.S. and EU cGMP standards. This state-of-the-art site will specialize in the production of human bone marrow-derived mesenchymal stem cells and neural stem cells. The facility spans a total area of 4,500 square meters and is expected to become operational in 2019. In the future, it will serve as a key platform for conducting multiple international, multi-center clinical trials, driving forward the advancement of stem cell-based drug development technologies.
According to incomplete statistics, there are currently 13 stem-cell drugs approved globally, yet none have been approved in China yet. Turning stem cells into viable medicines is the strategic development path that Jiuzhitang has chosen for its stem-cell product portfolio. To achieve this goal, Jiuzhitang plans to collaborate with top-tier hospitals across the country to conduct multi-center clinical trials focusing on neurological and cardiovascular diseases, ultimately paving the way for the commercialization of stem-cell-based therapies.
Meanwhile, Jiuzhitang has also signed cooperation agreements with Mexico’s Novastem Cell Technology Company and Kazakhstan’s ALTACO Cell Technology Company, respectively, to jointly establish an international stem cell research and development platform.
At the "Global Stem Cell Industry Development Summit Forum" held that day, 2004 Nobel laureate Aaron Ciechanover discussed "The New Medical Revolution: At What Cost Will We Cure All Diseases?"; international expert in clinical stem cell research Joseph Maroon provided detailed insights into "Can Stem Cells Serve as a Treatment for Traumatic Brain Injury?"; and Michael Levy, a renowned American pediatric neurosurgery chief, shared "An Analysis of Stem Cell Therapies for Stroke and Other Serious Conditions," highlighting the ongoing clinical trial progress on stem cell-based treatments specifically tailored for stroke indications.
Meanwhile, Zhang Yanan from Beijing Tiantan Hospital, Affiliated to Capital Medical University, presented the country's clinical trial plans and protocols for stem cells in neurology and neurosurgery. Tian Ye from the First Affiliated Hospital of Harbin Medical University discussed the promising applications of stem cells in cardiology, as well as the potential of exosomes and sonodynamic regulation. Yuan Baozhu, Director of the Cell Resource Storage and Research Center at the China National Institute for Food and Drug Control, provided insights into quality control measures for stem cells. (End)
Related News
Here is the title—h1 placeholder text
Copyright © Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.
Powered by: 300.cn SEO | Privacy Policy